Objective: To examine the efficacy of interferon therapy of hepatitis C in liver transplant recipients, to determine the effect of interferon on allograft rejection rates, and to examine the effect of the primary immunosuppressive agent (FK-506/cyclosporin) on the above. Design: A non-randomized consecutive patient treatment study. Patients: Fifty-two liver allograft recipients with hepatitis C virus (HCV) associated liver disease. All 52 patients had abnormal serum alanine aminotransferase (ALT) levels and in all, a liver biopsy confirmed the finding of post-transplant viral hepatitis.Interventions: All patients were treated with interferon at a dose of 5 million units three times weekly, administered subcutaneously for 6 months. Main outcome measures: Normalization of serum ALT levels was defined as a full response. A 50% reduction in serum ALT levels without normalization was defined as a partial response. Results: No difference in entry ALT levels or white blood cell counts was evident for the two groups based in the type of immunosuppression used, either cyclosporin or FK-506. Similarly, no difference in the response rate to interferon was observed based on the type of immunosuppression used. Improvement in ALT levels was not accompanied by a concomitant improvement in hepatic histology. Overall, Knodell scores for histology deteriorated in two-thirds of the patients despite interferon treatment. Conclusions: The use of interferon in liver transplant recipients reduces serum ALT levels but has little effect, if any, on hepatic allograft histopathology. In most patients, histology worsens despite interferon therapy. No difference in interferon response rates were observed between liver allograft recipients receiving either cyclosporin or FK-506.

Van Thiel, D., Baddour, N., Fagiuoli, S., Wright, H., Gavaler, J. (1994). Alpha-interferon treatment of hepatitis C in patients with liver allografts treated with either FK-506 or cyclosporin A. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 6(9), 787-791 [10.1097/00042737-199409000-00007].

Alpha-interferon treatment of hepatitis C in patients with liver allografts treated with either FK-506 or cyclosporin A

Fagiuoli S;
1994

Abstract

Objective: To examine the efficacy of interferon therapy of hepatitis C in liver transplant recipients, to determine the effect of interferon on allograft rejection rates, and to examine the effect of the primary immunosuppressive agent (FK-506/cyclosporin) on the above. Design: A non-randomized consecutive patient treatment study. Patients: Fifty-two liver allograft recipients with hepatitis C virus (HCV) associated liver disease. All 52 patients had abnormal serum alanine aminotransferase (ALT) levels and in all, a liver biopsy confirmed the finding of post-transplant viral hepatitis.Interventions: All patients were treated with interferon at a dose of 5 million units three times weekly, administered subcutaneously for 6 months. Main outcome measures: Normalization of serum ALT levels was defined as a full response. A 50% reduction in serum ALT levels without normalization was defined as a partial response. Results: No difference in entry ALT levels or white blood cell counts was evident for the two groups based in the type of immunosuppression used, either cyclosporin or FK-506. Similarly, no difference in the response rate to interferon was observed based on the type of immunosuppression used. Improvement in ALT levels was not accompanied by a concomitant improvement in hepatic histology. Overall, Knodell scores for histology deteriorated in two-thirds of the patients despite interferon treatment. Conclusions: The use of interferon in liver transplant recipients reduces serum ALT levels but has little effect, if any, on hepatic allograft histopathology. In most patients, histology worsens despite interferon therapy. No difference in interferon response rates were observed between liver allograft recipients receiving either cyclosporin or FK-506.
Articolo in rivista - Articolo scientifico
Interferon therapy; Liver transplantation; Viral hepatitis;
English
787
791
5
Van Thiel, D., Baddour, N., Fagiuoli, S., Wright, H., Gavaler, J. (1994). Alpha-interferon treatment of hepatitis C in patients with liver allografts treated with either FK-506 or cyclosporin A. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 6(9), 787-791 [10.1097/00042737-199409000-00007].
Van Thiel, D; Baddour, N; Fagiuoli, S; Wright, H; Gavaler, J
File in questo prodotto:
File Dimensione Formato  
vAN THIEL EJGH 1994 p. 787.pdf

Solo gestori archivio

Dimensione 378.19 kB
Formato Adobe PDF
378.19 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/353935
Citazioni
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 4
Social impact